139 373

Cited 2 times in

Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients

DC Field Value Language
dc.contributor.authorOh, CK-
dc.contributor.authorKim, SJ-
dc.contributor.authorKim, JH-
dc.contributor.authorLee, JH-
dc.date.accessioned2013-05-02-
dc.date.available2013-05-02-
dc.date.issued2012-
dc.identifier.issn1011-8934-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/8132-
dc.description.abstractDuring the past few years, new immunosuppressants, such as tacrolimus, mycophenolate mofetil (MMF) and basiliximab, have been shown to successfully decrease the incidence of acute rejection, possibly acting as potent substrates for safe steroid withdrawal. Therefore, clinical outcome of 3 months steroid withdrawal, while using the above immunosuppressants, was analyzed. Clinical trial registry No. was NCT 01550445. Thirty de novo renal transplant recipients were enrolled, and prednisolone was slowly withdrawn 3 months post-transplantation by 2.5 mg at every two weeks, until 8 weeks. During steroid withdrawal, 10 patients (30.0%) discontinued the protocol and they were maintained on steroid treatment. Among 20 steroid free patients, 8 patients (40.0%) re-started the steroid within 12 months post-transplantation. By the study endpoint, 12 (40%) recipients did not take steroid and survival of patients and grafts was 100%. In conclusion, in kidney transplant patients, 3 months steroid withdrawal while taking tacrolimus, basiliximab and mycophenolate mofetil was not associated with increased mortality or graft loss. Despite various causes of failure of steroid withdrawal during the follow-up period, it is a strategy well advised for kidney transplant recipients with regard to long-term steroid-related complications.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAnti-Inflammatory Agents/*therapeutic use-
dc.subject.MESHAntibodies, Monoclonal/therapeutic use-
dc.subject.MESHBlood Urea Nitrogen-
dc.subject.MESHCholesterol/blood-
dc.subject.MESHCreatinine/blood-
dc.subject.MESHFemale-
dc.subject.MESHGraft Rejection/mortality/*prevention & control-
dc.subject.MESHHumans-
dc.subject.MESHImmunosuppressive Agents/*therapeutic use-
dc.subject.MESH*Kidney Transplantation-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMycophenolic Acid/analogs & derivatives/therapeutic use-
dc.subject.MESHPrednisolone/*therapeutic use-
dc.subject.MESHRecombinant Fusion Proteins/therapeutic use-
dc.subject.MESHTacrolimus/therapeutic use-
dc.titleProspective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients-
dc.typeArticle-
dc.identifier.pmid22468094-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314843/-
dc.contributor.affiliatedAuthor오, 창권-
dc.contributor.affiliatedAuthor이, 종훈-
dc.type.localJournal Papers-
dc.identifier.doi10.3346/jkms.2012.27.4.337-
dc.citation.titleJournal of Korean medical science-
dc.citation.volume27-
dc.citation.number4-
dc.citation.date2012-
dc.citation.startPage337-
dc.citation.endPage342-
dc.identifier.bibliographicCitationJournal of Korean medical science, 27(4):337-342, 2012-
dc.identifier.eissn1598-6357-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Files in This Item:
22468094.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse